Baseline characteristics | Study participants (n = 28) |
---|---|
Age in years, median (IQR) | 21.0 (16.0; 23.0) |
Female, n (%) | 11 (39.3) |
Pseudomonas aeruginosa positivea, n (%) | 15 (53.6) |
Staphylococcus aureus (MSSA) positiveb, n (%) | 16 (57.1) |
Staphylococcus aureus (MRSA) positiveb, n | 0 |
Stenotrophomonas maltophilia positiveb, n (%) | 1 (3.6) |
Burkholderia cepacia positiveb, n (%) | 1 (3.6) |
Body mass index, median (IQR) | 18.3 (16.2; 19.6) |
Pancreatic insufficient, n (%) | 26 (92.9) |
Diabetes mellitus, n (%) | 10 (35.7) |
ABPA, n (%) | 1 (3.6) |
ΔF508/ΔF508, n (%) | 17 (60.7) |
ΔF508 compound heterozygote, n (%) | 7 (25.0) |
Othersc, n (%) | 4 (14.3) |
FVC, litres, median (IQR) | 2.5 (1.6; 2.8) |
FVC % predicted, median (IQR) | 66.0 (47.8; 73.6) |
FEV1, litres, median (IQR) | 1.4 (0.9; 1.9) |
FEV1 % predicted, median (IQR) | 46.0 (43.0; 58.0) |